KLK3 and benign prostatic hyperplasia: Compared to clinical parameters, AMACR was superior to PSA, f/t PSA (Figure 2C, AMACR vs. PSA, p = 0.001; AMACR vs. f/t PSA, p = 0.032), and PSAD but could not reach statistical significance (Figure 2C, AMACR vs. PSAD, p = 0.06) in detecting PCa from BPH.